drugset / Trial / NCT04661709

Summary

This is a double-blind, randomized placebo-controlled trial which aims to evaluate the efficacy and safety of Wen Xin granule in patients with unstable angina pectoris.

Timeline

Start
2021-03-01
Primary completion
2023-03-01
Completion
2023-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Wen Xin granule Unknown — Oral
Background Aspirin Small molecule 100 mg Oral
Background Atorvastatin Small molecule 20 mg Oral
Background Clopidogrel Small molecule 75 mg Oral
Background Isosorbide Mononitrate Other / unclassified 20 mg Oral
Background Metoprolol Other / unclassified 12.5 mg Oral
Background Metoprolol Other / unclassified 25 mg Oral
Background Nitroglycerin Unknown — —
Background Trimetazidine Small molecule 20 mg Oral